Mosby's 2014 Nursing Drug Reference (387 page)

BOOK: Mosby's 2014 Nursing Drug Reference
11.02Mb size Format: txt, pdf, ePub

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

terbinafine topical

 

terbutaline (Rx)

(ter-byoo′ta-leen)

Bricanyl

Func. class.:
Selective β
2
-agonist; bronchodilator

Chem. class.:
Catecholamine

Do not confuse:
terbutaline
/TOLBUTamide/terbinafine

ACTION:

Relaxes bronchial smooth muscle by direct action on β
2
-adrenergic receptors through the accumulation of cAMP at β-adrenergic receptor sites; bronchodilation, diuresis, CNS, cardiac stimulation occur; relaxes uterine smooth muscle

USES:

Bronchospasm

Unlabeled uses:
Premature labor, nonresponsive status asthmaticus in children (IV)

CONTRAINDICATIONS:

Hypersensitivity to sympathomimetics, closed-angle glaucoma, tachydysrhythmias

Precautions:
Pregnancy (B), breastfeeding, geriatric patients, cardiac disor
ders, hyperthyroidism, diabetes mellitus, prostatic hypertension, hypertension, seizure disorder

 

Black Box Warning:

Labor

DOSAGE AND ROUTES
Calculator
Bronchospasm

• Adult and child >12 yr:
PO
2.5-5 mg q8hr;
SUBCUT
0.25 mg q15-30min, max 0.5 mg in 4 hr

• Adolescent ≤15 yr and child ≥12 yr:
PO
2.5 mg tid, max 7.5 mg/day

• Child 6-11 yr (unlabeled):
PO
0.05 mg/kg q8hr, may increase slowly

Renal dose

• Adult:
PO
CCr 10-50 ml/min, 50% of dose; CCr <10 ml/min, avoid use

Tocolytic (preterm labor) (unlabeled)

• Adult:
SUBCUT
0.25 mg q20min to 6 hr, hold if pulse >120 bpm

Available forms:
Tabs 2.5, 5 mg; inj 1 mg/ml

Administer:

• 
With food; may be crushed

• 
2 hr before bedtime to avoid sleeplessness

IV route (unlabeled)

• 
Only used if subcut is ineffective

• 
IV after diluting each 5 mg/1 L D
5
W for inf

• 
IV, run 5 mcg/min; may increase 5 mcg q10min, titrate to response; after 1/2-1 hr, taper dose by 5 mcg; switch to PO as soon as possible

Y-site compatibilities:
Insulin (regular)

SIDE EFFECTS

CNS:
Tremors, anxiety, insomnia, headache, dizziness, stimulation

CV:
Palpitations, tachycardia, hypertension, dysrhythmias,
cardiac arrest, QT prolongation

GI:
Nausea, vomiting

META:
Hypokalemia, hyperglycemia

RESP:
Paradoxical bronchospasm, dyspnea

PHARMACOKINETICS

PO:
Onset 1/2 hr, peak 1-2 hr, duration 4-8 hr, half-life 3.4 hr

SUBCUT:
Onset 6-15 min, peak 1/2-1 hr, duration 1½-4 hr, half-life 5.7 hr

INTERACTIONS

• 
Hypertensive crisis: MAOIs

Increase:
effects of both products—other sympathomimetics

Decrease:
action—β-blockers; do not use together

Drug/Herb

Increase:
effect—green tea (large amounts), guarana

NURSING CONSIDERATIONS
Assess:

• 
Respiratory function: vital capacity, forced expiratory volume, ABGs, B/P, pulse, respiratory pattern, lung sounds, sputum before and after treatment

• 
Tolerance in patients receiving long-term therapy; dose may have to be changed; monitor for rebound bronchospasm

 
Paradoxical bronchospasm:
dyspnea, wheezing; keep emergency equipment nearby

• 
Labor:
maternal heart rate, B/P, contraction, fetal heart rate; can inhibit uterine contractions, labor; monitor for hypoglycemia

Perform/provide:

• 
Storage at room temp; do not use discolored sol

• 
Increase in fluids of >2 L/day

Evaluate:

• 
Therapeutic response: absence of dyspnea, wheezing

Teach patient/family:

• 
Not to use OTC medications because extra stimulation may occur

• 
About all aspects of product; to avoid smoking, smoke-filled rooms, persons with respiratory infections

• 
To increase fluids by >2 L/day; to allow 15 min between inhalation of product and inhaled product containing steroid

• 
To take on time; if missed, not to make up after 1 hr, to wait until next dose

Canada only   Side effects:
italics
= common;
bold
= life-threatening   
Nurse Alert

terconazole vaginal
antifungal

 

teriparatide (Rx)

(tah-ree-par′ah-tide)

Forteo

Func. class.:
Parathyroid hormone (rDNA)

Chem. class.:
Teriparatide

ACTION:

Contains human recombinant parathyroid hormone to stimulate new bone growth

USES:

Postmenopausal women with osteoporosis, men with primary or hypogonadal osteoporosis who are at high risk for fracture, glucocorticoid-induced osteoporosis

Unlabeled uses:
Hypoparathyroidism

CONTRAINDICATIONS:

Hypersensitivity, increased baseline risk for osteosarcoma (Paget’s disease, open epiphyses; previous bone radiation), bone metastases, history of skeletal malignancies, other metabolic bone diseases, preexisting hypercalcemia

Precautions:
Pregnancy (C), breastfeeding, children, urolithiasis, hypotension, use >2 yr, cardiac disease

 

Black Box Warning:

Secondary malignancy

DOSAGE AND ROUTES
Calculator

• Adult:
SUBCUT
20 mcg/day up to 2 yr (osteoporosis); long-term/lifetime use is recommended (glucocorticoid-induced osteoporosis)

Available forms:
Prefilled pen delivery device (delivers 20 mcg/day)

Administer:
SUBCUT route

• 
Give by SUBCUT using disposable pen only; inject in thigh or abdomen; lightly pinch fold of skin; insert needle; release skin; inject at 90-degree angle over 5 sec; rotate inj sites

• 
Have patient sit or lie down; orthostatic hypotension may occur

• 
Protect from freezing, light; refrigerate pen

SIDE EFFECTS

CNS:
Dizziness, headache, insomnia, depression, vertigo

CV:
Hypertension, angina, syncope

GI:
Nausea, diarrhea, dyspepsia, vomiting, constipation

INTEG:
Rash, sweating

MISC:
Pain, asthenia, hyperuricemia

MS:
Arthralgia, leg cramps, back/leg pain, weakness,
osteosarcoma (rare)

RESP:
Rhinitis, cough, pharyngitis, pneumonia, dyspnea

PHARMACOKINETICS

SUBCUT:
Extensively and rapidly absorbed, metabolized by liver, excreted by kidneys, terminal half-life 1 hr, onset rapid, peak 1/2 hr, duration 3 hr

INTERACTIONS

Increase:
digoxin toxicity: digoxin

Drug/Lab Test

Increase:
calcium, uric acid, urinary calcium

Decrease:
phosphorous, magnesium

NURSING CONSIDERATIONS
Assess:

 

Black Box Warning:

Secondary malignancy: osteosarcoma, dependent on length of treatment; those at higher risk for osteosarcoma should not use this product

• 
Uric acid, magnesium, creatinine, BUN, urine pH, vit D, phosphate for normal serum levels; serum calcium may be transiently increased after dosing (max at 4-6 hr after dose)

• 
Bone pain, headache, fatigue, changes in LOC, leg cramps

• 
Signs of persistent hypercalcemia:
nausea, vomiting, constipation, lethargy, muscle weakness

• 
Nutritional status: diet for sources of vit D (milk, some seafood), calcium (dairy products, dark green vegetables), phosphates (dairy products)

Perform/provide:

• 
Store refrigerated, do not freeze; may be used for 28 days after first inj

Evaluate:

• 
Therapeutic response: increased bone mineral density

Teach patient/family:

• 
About the symptoms of hypercalcemia

• 
About foods rich in calcium, vit D

• 
How to use delivery device, dispose of needles; not to share pen with others, to use at same time of day

• 
To sit or lie down if dizziness or fast heartbeat occurs after 1st few doses

• 
To rotate administration sites

• 
To store pen in refrigerator, pen may be used for 28 days

Other books

Murder of a Sweet Old Lady by Denise Swanson
Once Upon a Time by Barbara Fradkin
Freddie Ramos Stomps the Snow by Jacqueline Jules
Murder by Proxy by Brett Halliday
Gemini Falling by Eleanor Wood
Conspiracy in Kiev by Noel Hynd
A Chance of Fate by Cummings, H. M.
A Cat Tells Two Tales by Lydia Adamson